文献速递临床免疫质量管理与危急值

免疫分析法与间接免疫荧光法初筛结缔组织病的层次双变量诊断准确性Meta分析

A hierarchical bivariate meta-analysis of diagnostic test accuracy to provide direct comparisons of immunoassays vs. indirect immunofluorescence for initial screening of connective tissue diseases.
PubMed 文献 · Clin Chem Lab Med · 2020-04-30

该系统评价与层次双变量Meta分析直接比较了间接免疫荧光法(IIF)检测抗核抗体与免疫分析法(ELISA、FEIA、CLIA、MIA)初筛结缔组织病的诊断准确性。FEIA和CLIA特异性优于IIF,IIF阴性有助于排除结缔组织病,FEIA或CLIA阳性有助于支持诊断。

要点

  • FEIA特异性显著高于IIF,阳性结果有助于支持结缔组织病诊断。
  • CLIA敏感性与IIF(1:80)相似而特异性更高,但预测区间宽需更多数据。
  • IIF阴性结果有助于排除结缔组织病,ELISA与IIF敏感性均好但特异性低。

核心结论

  • FEIA和CLIA相比IIF具有良好特异性,阳性FEIA或CLIA检测有助于支持结缔组织病诊断。
  • 阴性IIF检测有助于排除结缔组织病。

研究设计与样本

  • 系统文献综述纳入报告IIF与ELISA、FEIA、CLIA或MIA诊断准确性数据的横断面或病例对照研究。
  • 采用按检测方法随机效应的层次双变量混合效应模型进行Meta分析。

主要发现

  • IIF与ELISA直接比较(5项研究,2321例患者):ELISA敏感性90.3%(95%CI 80.5%, 95.5%),IIF 1:80为86.8%(95%CI 81.8%, 90.6%),p=0.4;ELISA特异性56.9%(95%CI 40.9%, 71.5%),IIF 1:80为68.0%(95%CI 39.5%, 87.4%),p=0.5。
  • FEIA敏感性低于IIF(1:80 p=0.005;1:160 p=0.051),但特异性更高:7项研究n=12,311,FEIA 93.6%(95%CI 89.9%, 96.0%)vs IIF 1:80 72.4%(95%CI 62.2%, 80.7%),p<0.001;7项研究n=3251,FEIA 93.5%(95%CI 91.1%, 95.3%)vs IIF 1:160 81.1%(95%CI 73.4%, 86.9%),p<0.0001。
  • CLIA敏感性与IIF(1:80)相似而特异性更高(4项研究,n=1981:敏感性85.9% [95%CI 64.7%, 95.3%],p=0.86;特异性86.1% [95%CI 78.3%, 91.4%]),但预测区间宽,需更多数据才能对CLIA与IIF比较做出可靠推断。
  • MIA与IIF比较的研究过少无法进行Meta分析(MIA敏感性范围73.7%-86%;特异性53%-91%)。

关键数值与推荐

  • FEIA vs IIF 1:80:敏感性p=0.005,特异性p<0.001(7项研究,n=12,311)。
  • FEIA vs IIF 1:160:敏感性p=0.051,特异性p<0.0001(7项研究,n=3251)。
  • CLIA vs IIF 1:80:敏感性p=0.86,4项研究n=1981。
  • IIF与ELISA比较:敏感性p=0.4,特异性p=0.5(5项研究,2321例患者)。

临床怎么用

  • FEIA或CLIA阳性结果可用于支持结缔组织病诊断。
  • IIF阴性结果可用于排除结缔组织病。
  • ELISA与IIF敏感性均好但特异性低,结果解释需结合临床。

局限性

  • CLIA与IIF比较的预测区间宽,需更多数据才能做出可靠推断。
  • MIA与IIF比较的研究过少,无法进行Meta分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare indirect immunofluorescence (IIF) for antinuclear antibodies (ANA) against immunoassays (IAs) as an initial screening test for connective tissue diseases (CTDs). METHODS: A systematic literature review identified cross-sectional or case-control studies reporting test accuracy data for IIF and enzyme-linked immunosorbent assays (ELISA), fluorescence enzyme immunoassay (FEIA), chemiluminescent immunoassay (CLIA) or multiplex immunoassay (MIA). The meta-analysis used hierarchical, bivariate, mixed-effect models with random-effects by test. RESULTS: Direct comparisons of IIF with ELISA showed that both tests had good sensitivity (five studies, 2321 patients: ELISA: 90.3% [95% confidence interval (CI): 80.5%, 95.5%] vs. IIF at a cut-off of 1:80: 86.8% [95% CI: 81.8%, 90.6%]; p = 0.4) but low specificity, with considerable variance across assays (ELISA: 56.9% [95% CI: 40.9%, 71.5%] vs. IIF 1:80: 68.0% [95% CI: 39.5%, 87.4%]; p = 0.5). FEIA sensitivity was lower than IIF sensitivity (1:80: p = 0.005; 1:160: p = 0.051); however, FEIA specificity was higher (seven studies, n = 12,311, FEIA 93.6% [95% CI: 89.9%, 96.0%] vs. IIF 1:80 72.4% [95% CI: 62.2%, 80.7%]; p < 0.001; seven studies, n = 3251, FEIA 93.5% [95% CI: 91.1%, 95.3%] vs. IIF 1:160 81.1% [95% CI: 73.4%, 86.9%]; p < 0.0001). CLIA sensitivity was similar to IIF (1:80) with higher specificity (four studies, n = 1981: sensitivity 85.9% [95% CI: 64.7%, 95.3%]; p = 0.86; specificity 86.1% [95% CI: 78.3%, 91.4%]). More data are needed to make firm inferences for CLIA vs. IIF given the wide prediction region. There were too few studies for the meta-analysis of MIA vs. IIF (MIA sensitivity range 73.7%-86%; specificity 53%-91%). CONCLUSIONS: FEIA and CLIA have good specificity compared to IIF. A positive FEIA or CLIA test is useful to support the diagnosis of a CTD. A negative IIF test is useful to exclude a CTD.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Orme ME, Andalucia C, Sjölander S, et al. A hierarchical bivariate meta-analysis of diagnostic test accuracy to provide direct comparisons of immunoassays vs. indirect immunofluorescence for initial screening of connective tissue diseases. Clin Chem Lab Med. 2020. PMID: 32352399. doi:10.1515/cclm-2020-0094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。